Gunasekaran Kannan

This inventor holds 41 USPTO granted patents and 23 published patent applications, plus 2 CIPO patents and 20 EPO patents, primarily in Biotherapeutic Proteins. Top assignees: Amgen Inc., Denali Therapeutics Inc., Other. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gunasekaran Kannan. Retrieved from https://idiyas.com/inventor/gunasekaran-kannan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 41 (Patent Applications = 23)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 20 (Patent Applications = 16)

Average Co-Inventor Count = 4.1

ph-index = 12

Forward Citations = 580(Granted Patents)

Location History:

Issaquah, WA (US) (2013)
Westlake Village, CA (US) (2015 - 2016)
Newbury, CA (US) (2017)
Newbury Park, CA (US) (2016 - 2019)
Thousand Oaks, CA (US) (2019 - 2023)
South San Francisco, CA (US) (2023)
Daly City, CA (US) (2016 - 2024)

Company Filing History:

Denali Therapeutics Inc.

patents

1 out of 834,513

Other

patents

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Anti-TL1A Antibodies

Interleukin-2 Muteins

GDF-15 Polypeptides

Bi-specific Antigen Binding Proteins

Heterodimeric Immunoglobulins

BCMA Antigen Binding Proteins

Fc Variants

Aglycosylated Fc-Containing Polypeptides

Proteins Specific for BAFF

Tumor Treatment

T-Regulatory Cells

Antibody Fc-Heterodimeric Molecules

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12667606 - FORMULATIONS OF PROTEIN MOLECULES COMPRISING IDURONATE 2-SULFATASE (2026-06-30),

2. 12636363 - ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF (2026-05-26),

3. 12552877 - Anti-TL1A antibodies and uses thereof (2026-02-17),

4. 12479930 - PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF (2025-11-25),

5. 11976103 - Interleukin-2 muteins for the expansion of T-regulatory cells (2024-05-07),

6. 11976102 - Interleukin-2 muteins for the expansion of T-regulatory cells (2024-05-07),

7. 11919964 - Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof (2024-03-05),

8. 11884944 - Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof (2024-01-30),

9. 11739131 - Growth differentiation factor 15 (GDF-15) polypeptides (2023-08-29),

10. 11643446 - Progranulin variants (2023-05-09),

11. 11541103 - Interleukin-21 mutein/ anti-PD-1 antibody conjugates (2023-01-03),

12. 11518808 - Anti-PD-1 antibodies and methods of treatment (2022-12-06),

13. 11492417 - Proteins specific for BAFF and B7RP1 and uses thereof (2022-11-08),

14. 11466078 - Heterodimeric immunoglobulins (2022-10-11),

15. 11248052 - Antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor (2022-02-15),

Title: Gunasekaran Kannan: A Pioneer in T-Cell Regulation

Introduction

Gunasekaran Kannan, based in Daly City, California, is an accomplished inventor with a significant contribution to the field of immunology. With a remarkable portfolio of 37 patents, Kannan's work primarily focuses on the development of innovative therapies that enhance the regulation of T regulatory cells, vital for maintaining immune system balance.

Latest Patents

Among his latest patents, Kannan presents groundbreaking inventions related to Interleukin-2 muteins. These inventions include IL-2 muteins and IL-2 mutein Fc-fusion molecules that are designed to preferentially expand and activate T regulatory cells, enabling large-scale production capabilities. His research also delves into variant human IgG1 Fc molecules that maintain high stability and reduced effector function, even in the absence of glycosylation at N297. Furthermore, Kannan has developed linker peptides that are glycosylated within mammalian cells, along with methods for producing and utilizing these innovative compositions.

Career Highlights

Kannan has worked with leading biopharmaceutical companies, including Amgen Inc. and Denali Therapeutics Inc., where he has been instrumental in advancing therapeutic solutions for various diseases through his patent portfolio. His extensive experience has positioned him as a key figure in the field of biotechnology.

Collaborations

Throughout his career, Kannan has collaborated with notable colleagues, including Zhulun Wang and Kenneth William Walker. These collaborations have allowed for the cross-pollination of ideas and innovation, driving progress in their shared field of research.

Conclusion

Gunasekaran Kannan's contributions, particularly in the realm of T regulatory cell expansion, have the potential to greatly impact immunotherapy and enhance therapeutic outcomes for patients. His patents reflect a deep commitment to innovation and the advancement of medical science, solidifying his reputation as a leader in his area of expertise.

Profile summary based on public USPTO records.